SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Abgenix, Inc. (ABGX)
An SI Board Since December 1998
Posts SubjectMarks Bans
590 38 0
Emcee:  Henry Niman Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
515John, It is not my intention to compare E trials results with P report one. As Miljenko Zuanic-11/3/2005
514MJ Gonna stick both feet in my mouth ..... Your point INFERS that both drugs John McCarthy-11/3/2005
513For comparison: (ONXX)100% (24 versus 12) is 0.000001 (ABGX) 46% (X versus Y)iMiljenko Zuanic-11/3/2005
512Thanks Wilder. I will try. MiljenkoMiljenko Zuanic-11/3/2005
511AMGN stuck to their endpoint analysis. Dodged all questions about mean/median akeokalani'nui-11/3/2005
510<<If the “tumor progression rate” was slowed by 46% in the Pani arm relatiMiljenko Zuanic-11/3/2005
509<i>So many posts, and I still do not see numbers for TTP?</i> PFS, DewDiligence_on_SI-11/3/2005
508Can't exactly recall, but I think 100% patients progressed at 8 weeks.keokalani'nui-11/3/2005
507[Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvatuck-11/3/2005
506><i>So, IMCL prophet, when you will admit that you are full of BS? You DewDiligence_on_SI-11/3/2005
505So many posts, and I still do not see numbers for TTP? 46% of what number? MilMiljenko Zuanic-11/3/2005
504So, IMCL prophet, when you will admit that you are full of BS? You are lost, bigMiljenko Zuanic-11/3/2005
503EDIT Panitumumab, given intravenously, is a monoclonal antibody which works by John McCarthy-11/3/2005
502EDIT Thousand Oaks, Calif.-based Amgen said the study results mean its drug isJohn McCarthy-11/3/2005
501From Briefing.com news update finance.messages.yahoo.com 14:30 IMCL Imclone: FuRealMuLan-11/3/2005
500CC is very strong. Unambiguous results. Dramatic drug effect on PFS. KM curvekeokalani'nui-11/3/2005
499Goldman Sachs - from Yahoo post ... finance.messages.yahoo.com <<<&lJohn McCarthy-11/3/2005
498yes, it is nice to be on this side today. appreciate your help as always.mopgcw-11/3/2005
497Late into the office....Nice nice nice! Lighten up now? For me, my own answer keokalani'nui-11/3/2005
496Thanks, John. Rickscaram(o)uche-11/3/2005
495Panitumumab - Abstract 1123: Panitumumab, a fully human antibody, combined witJohn McCarthy-11/3/2005
494Panitumumab - Abstract 653: First line therapy of Panitumumab, a fully human antJohn McCarthy-11/3/2005
493(p less than 0.000000001) wow. That looks a lot like my bank account. Just kenhott-11/3/2005
492Thank you very much. regards, JohnJohn McCarthy-11/3/2005
491lighten up now? wild ride for sure. so much for the leak nonsense.mopgcw-11/3/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News